

# NOVARTIS AG

ISIN: CH0012005267

WKN: 1200526

Asset Class: **Stock**

## Company

2024/10/18 17:30:09



Price

**100.98**

CHF

Difference

0.02%(0.02)



## Contact Details

NOVARTIS AG Tel: +41-61-324-11-11

- - Fax: +

Lichtstrasse 35 Web: <http://www.novartis.com>

4056 Basel E-mail: -

## Company Profile

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

## Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures              | 2023           |                        | 2022            |                        | 2021            |                        |
|--------------------------------|----------------|------------------------|-----------------|------------------------|-----------------|------------------------|
|                                | Assets         | Liabilities and equity | Assets          | Liabilities and equity | Assets          | Liabilities and equity |
| Current assets                 | 25,654,333,000 |                        | 34,149,132,000  |                        | 41,655,955,000  |                        |
| Common stock capital           |                | 694,361,000            |                 | 823,428,000            |                 | 820,946,000            |
| Fixed assets                   | 61,729,135,000 |                        | 78,507,846,000  |                        | 82,154,750,000  |                        |
| Equity capital of a company    |                | 39,347,137,000         |                 | 54,978,159,000         |                 | 61,796,015,000         |
| Cash and cash equivalents      | 11,272,218,000 |                        | 6,954,728,000   |                        | 11,304,638,000  |                        |
| Accrued liabilities            |                | 2,802,694,000          |                 | 3,079,065,000          |                 | 4,279,671,000          |
| Other assets                   | -              |                        | -               |                        | -               |                        |
| Current liabilities            |                | 22,211,143,000         |                 | 26,512,531,000         |                 | 27,524,019,000         |
| Prepayments and accrued income | -              |                        | -               |                        | -               |                        |
| Non-current liabilities        |                | 25,825,188,000         |                 | 31,166,287,000         |                 | 34,490,672,000         |
| Different income               |                | -                      |                 | -                      |                 | -                      |
| Other liabilities              |                | 1,004,088,000          |                 | 1,459,965,000          |                 | 1,343,946,000          |
| Total assets                   | 87,383,469,000 | 87,383,469,000         | 112,656,978,000 | 112,656,978,000        | 123,810,706,000 | 123,810,706,000        |

## Balance notes

|                     | 2023    | 2022    | 2021    |
|---------------------|---------|---------|---------|
| Accounting standard | IFRS    | IFRS    | IFRS    |
| Employees           | 76,057  | 101,703 | 104,323 |
| Equity ratio        | 45.11%  | 48.87%  | 50.03%  |
| Debt-equity ratio   | 121.69% | 104.63% | 99.86%  |

## Others

|                  | 2023  | 2022   | 2021   |
|------------------|-------|--------|--------|
| Tax Expense Rate | 6.03% | 16.90% | 19.62% |

**Income statement**

|  | 2023           | 2022           | 2021           |
|--|----------------|----------------|----------------|
| <b>Turnover</b>  | 40,834,735,000 | 48,273,766,000 | 47,199,917,000 |
| <b>Net income</b>  | 7,699,648,000  | 6,642,477,000  | 21,961,593,000 |
| <b>EBIT</b>  | 8,974,456,255  | 9,184,165,649  | 11,320,325,631 |
| <b>Operating income before taxes</b>                                 | 8,210,082,000  | 8,003,445,000  | 9,872,248,000  |
| <b>Cash Flow</b>   | 12,992,707,000 | 13,596,306,000 | 13,778,909,000 |
| <b>Net interest income</b>   | -223,764,000   | -627,477,000   | -766,155,000   |
| <b>Research and development expenses</b>                             | 7,389,613,000  | 8,484,798,000  | 8,722,101,000  |
| <b>Income taxes</b>  | 495,157,000    | 1,352,372,000  | 1,937,330,000  |
| <b>Result from investments in subsidiaries, associates and other</b> | -11,682,000    | -8,595,000     | 14,023,932,000 |
| <b>Revenues per employee</b>   | 571,312        | 505,080        | 481,442        |

**Board of Directors**

|                     |                                      |
|---------------------|--------------------------------------|
| Charles Sawyers     | Member of the administrative board   |
| Nancy Andrews       | Member of the administrative board   |
| Simon Moroney       | Member of the administrative board   |
| Ana de Pro Gonzalo  | Member of the administrative board   |
| Bridgette Heller    | Member of the administrative board   |
| Daniel Hochstrasser | Member of the administrative board   |
| Frans van Houten    | Member of the administrative board   |
| John Young          | Member of the administrative board   |
| Mary Doherty        | Member of the administrative board   |
| Patrice Bula        | Member of the administrative board   |
| Ton Büchner         | Member of the administrative board   |
| William Winters     | Member of the administrative board   |
| Hans Jörg Reinhardt | Chairman of the administrative board |

**Members of Management Board**

|                         |                               |
|-------------------------|-------------------------------|
| Vasant (Vas) Narasimhan | Chairman of Managing Board    |
| Klaus Moosmayer         | Member of Executive Committee |
| Steffen Lang            | Member of Executive Committee |
| Aharon Gal              | Member of Executive Committee |
| Fiona H. Marshall       | Member of Executive Committee |
| Harry Kirsch            | Member of Executive Committee |
| Karen Hale              | Member of Executive Committee |
| Kees Roks               | Member of Executive Committee |
| Lutz Hegemann           | Member of Executive Committee |
| Michelle Weese          | Member of Executive Committee |
| Patrick Horber          | Member of Executive Committee |
| Rob Kowalski            | Member of Executive Committee |
| Shreeram Aradhye        | Member of Executive Committee |
| Victor Bulto            | Member of Executive Committee |